Ridinilazole, a narrow spectrum antibiotic for treatment of Clostridioides difficile infection, enhances preservation of microbiota-dependent bile acids

Antibiotic treatment is a standard therapy for Clostridioides difficile infection, but dysbiosis of the gut microbiota due to antibiotic exposure is also a major risk factor for the disease. Following an initial episode of C. difficile infection, a relentless cycle of recurrence can occur, where per...

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Xi, Yanagi, Karin, Kane, Anne V., Alden, Nicholas, Lei, Ming, Snydman, David R., Vickers, Richard J., Lee, Kyongbum, Thorpe, Cheleste M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Physiological Society 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500266/
https://www.ncbi.nlm.nih.gov/pubmed/32597706
http://dx.doi.org/10.1152/ajpgi.00046.2020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500266/
https://www.ncbi.nlm.nih.gov/pubmed/32597706
http://dx.doi.org/10.1152/ajpgi.00046.2020

Ejemplares similares